Skip to Content
Orphic
/

Ingredient Screening

What it does

Given an efficacy goal (“inhibit melanogenesis”, “improve barrier function”, “lower postprandial glucose”), it produces a set of candidates worth pursuing, each with a stated reason for being on the list.

How it works

  1. Anchor the mechanism — resolve the goal to concrete targets and pathways instead of stopping at “antioxidant”.
  2. List candidates — from the knowledge graph, INCI libraries, ethnobotanical leads, and analysis of existing products.
  3. Evidence the mechanism — literature, clinical trials, and patents; key claims pass evidence grading.
  4. Safety and regulatory gates — safety data, adverse events, additive/supplement registry status, target-market compliance.
  5. Feasibility — supplier availability, retail eligibility, known product precedent, co-formulation precedent.
  6. Rank and self-audit — order by evidence strength and feasibility, then audit the list for weak evidence dressed up as strong.

What you get

A prioritized shortlist (ingredient, mechanism, evidence grade, safety and regulatory status, supply), the rationale behind each inclusion or exclusion, a bibliography, and optionally a deck.

Limits

  • Computational predictions (docking, similarity, connectivity analysis) inform ranking; they are not proof of activity.
  • The shortlist is an R&D starting point, not a purchasing decision — bench validation and commercial confirmation still apply.